comparemela.com


Takeda FY20 Profit Surges, Revenue Down; Sees Weak Profit, Higher Revenues In FY21
Earnings per share were 241 yen, up 747.3 percent from last year.
Core net profit was 655.5 billion yen or 420 yen per share, up 9 percent from last year.
Operating profit for the year grew 407.2 percent year-on-year to 509.3 billion yen or about $4.6 billion. Core operating profit was 967.9 billion yen or about $8.8 billion, up 0.6 percent from the previous year.
Revenue was 3.20 trillion yen or about $28.9 billion, down 2.8 percent from last year. On an underlying basis, revenue grew 2.2 percent, driven by the growth of Takeda's 14 global brands, up 16 percent year-on-year.
For fiscal 2021 ending March 31, 2022, the company projects net profit of 250 billion yen or 160 yen per share, core earnings per share of 394 yen, operating profit of 488 billion yen, and core operating profit of 930 billion yen, all lower than the previous year.

Related Keywords

Tokyo ,Japan ,Christophe Weber ,Japan Takeda Pharmaceutical Co ,Takeda Pharmaceutical ,Chief Executive Officer Christophe Weber ,டோக்கியோ ,ஜப்பான் ,கிறிஸ்டோஃப் வெபர் ,ஜப்பான் டாகேடா மருந்து இணை ,டாகேடா மருந்து ,தலைமை நிர்வாகி அதிகாரி கிறிஸ்டோஃப் வெபர் ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.